ACHILLION PHARMACEUTICALS INC: 10-Q filed 2011-11-08
What ACHILLION PHARMACEUTICALS INC reported in its quarterly report filed 2011-11-08 (fiscal Q3 2011): 27 published measures, 70 facts as tagged in accession 0001193125-11-302125.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2011-11-08
- Fiscal period
- fiscal Q3 2011
- Accession
- 0001193125-11-302125 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACHILLION PHARMACEUTICALS INC filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 93,355,000 | USD | |
| At 2010-12-31 | 58,235,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 11,160,000 | USD | |
| At 2010-12-31 | 7,691,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 82,195,000 | USD | |
| At 2010-12-31 | 50,544,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 23,388,000 | USD | |
| At 2010-12-31 | 25,373,000 | USD | |
| At 2010-09-30 | 27,684,000 | USD | |
| At 2009-12-31 | 9,712,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -10,438,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -31,821,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -7,217,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -19,237,000 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | -25,652,000 | USD | 273 |
| 2010-01-01 to 2010-09-30 | -18,148,000 | USD | 273 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 64,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 185,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 170,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 431,000 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 61,441,000 | USD | 273 |
| 2010-01-01 to 2010-09-30 | 70,924,000 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | -37,774,000 | USD | 273 |
| 2010-01-01 to 2010-09-30 | -34,804,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | -263,215,000 | USD | |
| At 2010-12-31 | -231,394,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 1,060,000 | USD | |
| At 2010-12-31 | 468,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 1,984,000 | USD | 273 |
| 2010-01-01 to 2010-09-30 | 1,459,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -10,473,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -31,900,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | -7,177,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | -19,047,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 67,265,000 | USD | |
| At 2010-12-31 | 57,498,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 9,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 35,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 67,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 243,000 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 8,406,000 | USD | |
| At 2010-12-31 | 5,202,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 4,175,000 | USD | |
| At 2010-12-31 | 2,672,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 10,537,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 32,085,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 7,347,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 19,478,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 8,615,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 25,504,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 5,657,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 14,431,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 69,743,000 | shares | |
| At 2010-12-31 | 58,376,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 345,383,000 | USD | |
| At 2010-12-31 | 281,878,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | -43,000 | USD | |
| At 2010-12-31 | 2,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 4,092,000 | USD | |
| At 2010-12-31 | 2,061,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-09-30 | 2,033,000 | USD | |
| At 2010-12-31 | 2,052,000 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | 1,922,000 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 6,581,000 | USD | 273 |
| 2010-07-01 to 2010-09-30 | 1,690,000 | USD | 92 |
| 2010-01-01 to 2010-09-30 | 5,047,000 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 236,000 | USD | 273 |
| 2010-01-01 to 2010-09-30 | 539,000 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-09-30 | 1,396,000 | USD | 273 |
| 2010-01-01 to 2010-09-30 | 414,000 | USD | 273 |
Inspect the source
- Entity
- ACHILLION PHARMACEUTICALS INC / CIK 0001070336
- Captured
- SEC response SHA-256
1fee9803c301c02de466ca37880d58ca899922fc422d8956b099af57f6ac02ed
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001070336.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))